Table 3.

TEAEs with an incidence of ≥5% in safety analysis set (n = 65)

AE	All TEAEs		Drug-related TEAEs
	All grade n (%)	Grade ≥3 n (%)	All grade n (%)	Grade ≥3 n (%)
Hematologic
Anemia	16 (24.6)	10 (15.4)	8 (12.3)	4 (6.2)
Thrombocytopenia	14 (21.5)	9 (13.8)	8 (12.3)	4 (6.2)
Neutropenia	11 (16.9)	8 (12.3)	8 (12.3)	6 (9.2)
Leukopenia	7 (10.8)	6 (9.2)	3 (4.6)	3 (4.6)
Lymphopenia	7 (10.8)	6 (9.2)	3 (4.6)	2 (3.1)
Nonhematologic
Pyrexia	27 (41.5)	2 (3.1)	10 (15.4)	1 (1.5)
Decreased appetite	13 (20.0)	1 (1.5)	7 (10.8)	0
Aspartate aminotransferase increased	12 (18.5)	2 (3.1)	11 (16.9)	2 (3.1)
Constipation	12 (18.5)	0	3 (4.6)	0
Rash	10 (15.4)	2 (3.1)	3 (4.6)	1 (1.5)
Alanine aminotransferase increased	10 (15.4)	0	10 (15.4)	0
Malaise	9 (13.8)	0	9 (13.8)	0
Delirium	8 (12.3)	2 (3.1)	6 (9.2)	2 (3.1)
Hypokalemia	7 (10.8)	3 (4.6)	2 (3.1)	1 (1.5)
Hypoalbuminemia	7 (10.8)	1 (1.5)	0	0
Vomiting	7 (10.8)	0	4 (6.2)	0
Fatigue	7 (10.8)	2 (3.1)	4 (6.2)	1 (1.5)
Pruritus	7 (10.8)	1 (1.5)	0	0
Diarrhea	6 (9.2)	0	3 (4.6)	0
Upper respiratory tract infection	6 (9.2)	0	2 (3.1)	0
Nasopharyngitis	6 (9.2)	0	0	0
Fall	6 (9.2)	0	0	0
Peripheral sensory neuropathy	5 (7.7)	0	4 (6.2)	0
Hyponatremia	5 (7.7)	3 (4.6)	1 (1.5)	0
Dizziness	5 (7.7)	0	2 (3.1)	0
Headache	5 (7.7)	0	1 (1.5)	0
Nausea	5 (7.7)	0	3 (4.6)	0
Hypertension	4 (6.2)	4 (6.2)	0	0
Hypophosphatemia	4 (6.2)	3 (4.6)	0	0
Pharyngitis	4 (6.2)	2 (3.1)	1 (1.5)	1 (1.5)
Abdominal pain	4 (6.2)	2 (3.1)	1 (1.5)	0
Hyperkalemia	4 (6.2)	2 (3.1)	2 (3.1)	0
Dysgeusia	4 (6.2)	0	4 (6.2)	0
Insomnia	4 (6.2)	0	2 (3.1)	0
Rhinorrhea	4 (6.2)	0	0	0